- Home
- RYTM vs VRNS Comparison
RYTM vs VRNS Comparison
Compare RYTM & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | VRNS |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.3B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RYTM | VRNS |
|---|---|---|
| Price | $88.80 | $46.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 24 |
| Target Price | ★ $140.35 | $51.45 |
| AVG Volume (30 Days) | 714.2K | ★ 1.4M |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $270,288,000.00 |
| Revenue This Year | $66.00 | $18.33 |
| Revenue Next Year | $78.72 | $18.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.35 |
| 52 Week Low | $74.50 | $19.70 |
| 52 Week High | $122.20 | $63.80 |
Technical Indicators
Market Signals| Indicator | RYTM | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 49.21 |
| Support Level | $82.43 | $44.40 |
| Resistance Level | $92.51 | $48.85 |
| Average True Range (ATR) | 3.39 | 1.90 |
| MACD | -0.22 | -0.27 |
| Stochastic Oscillator | 24.07 | 42.00 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.